Department of Experimental Medical Science, Lung Biology Unit , Lund University , Lund , Sweden.
Lund Stem Cell Center, Lund University , Lund , Sweden.
BMJ Open Respir Res. 2014 May 17;1(1):e000027. doi: 10.1136/bmjresp-2014-000027. eCollection 2014.
Mesenchymal stem cells (MSC) have not only been implicated in the development of lung diseases, but they have also been proposed as a future cell-based therapy for lung diseases. However, the cellular identity of the primary MSC in human lung tissues has not yet been reported. This study therefore aimed to identify and characterise the 'bona fide' MSC in human lungs and to investigate if the MSC numbers correlate with the development of bronchiolitis obliterans syndrome in lung-transplanted patients.
Primary lung MSC were directly isolated or culture-derived from central and peripheral transbronchial biopsies of lung-transplanted patients and evaluated using a comprehensive panel of in vitro and in vivo assays.
Primary MSC were enriched in the CD90/CD105 mononuclear cell fraction with mesenchymal progenitor frequencies of up to four colony-forming units, fibroblast/100 cells. In situ staining of lung tissues revealed that CD90/CD105 MSCs were located perivascularly. MSC were tissue-resident and exclusively donor lung-derived even in biopsies obtained from patients as long as 16 years after transplantation. Culture-derived mesenchymal stromal cells showed typical in vitro MSC properties; however, xenotransplantation into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice showed that lung MSC readily differentiated into adipocytes and stromal tissues, but lacked significant in vivo bone formation.
These data clearly demonstrate that primary MSC in human lung tissues are not only tissue resident but also tissue-specific. The identification and phenotypic characterisation of primary lung MSC is an important first step in identifying the role of MSC in normal lung physiology and pulmonary diseases.
间充质干细胞(MSC)不仅与肺部疾病的发展有关,而且还被提议作为肺部疾病的未来细胞治疗方法。然而,人肺组织中原始 MSC 的细胞表型尚未报道。因此,本研究旨在鉴定和表征人肺中的“真正”MSC,并研究 MSC 数量是否与肺移植患者发生闭塞性细支气管炎综合征的发展相关。
直接从肺移植患者的支气管内中央和外周活检中分离或培养衍生的原代肺 MSC,并使用全面的体外和体内检测方法进行评估。
原代 MSC 在 CD90/CD105 单核细胞群中富集,间充质祖细胞频率高达 4 个集落形成单位/100 个细胞。肺组织原位染色显示 CD90/CD105 MSC 位于血管周围。MSC 是组织驻留细胞,即使在移植后长达 16 年的患者活检中,也仅来源于供体肺。培养衍生的间充质基质细胞显示出典型的 MSC 体外特性;然而,将其异种移植到非肥胖糖尿病/严重联合免疫缺陷(NOD/SCID)小鼠中表明,肺 MSC 容易分化为脂肪细胞和基质组织,但缺乏明显的体内成骨作用。
这些数据清楚地表明,人肺组织中的原代 MSC 不仅是组织驻留细胞,而且是组织特异性的。鉴定和表型特征分析原代肺 MSC 是确定 MSC 在正常肺生理学和肺部疾病中的作用的重要第一步。